FCM
BBNX

Farallon Capital Management’s Beta Bionics BBNX Stock Holding History

Farallon Capital Management’s Portfolio BBNX Stock Details BBNX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$36.2M Sell
3,607,920
-706,000
-16% -$10.4M 0.21% 51
2025
Q4 		$131M Hold
4,313,920
– – 0.6% 42
2025
Q3 		$85.7M Buy
4,313,920
+110,000
+3% +$1.93M 0.35% 47
2025
Q2 		$61.2M Buy
4,203,920
+871,700
+26% +$12.3M 0.26% 51
2025
Q1 		$40.8M Buy
+3,332,220
New +$62.1M 0.2% 61

Other funds holding BBNX

EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
SCV
Sands Capital Ventures Arlington, Virginia $421M AUM 26.25% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
EP
Eversept Partners New York $1.9B AUM 121.13% 1-Year Est. Return

Farallon Capital Management's BBNX Position: Q1 2026 in Review

Farallon Capital Management reduced its Beta Bionics (BBNX) stake by 16% in Q1 2026, selling an estimated $10.4M and leaving 3,607,920 shares worth $36.2M. The position accounts for 0.21% of the portfolio, ranked #51.

Farallon Capital Management first reported a position in BBNX in Q1 2025 and has held it in 5 quarters since. The position peaked at $131M in Q4 2025. 130 funds tracked by Wall St. Rank hold BBNX as of Q1 2026.

  • Farallon Capital Management held 3,607,920 shares of Beta Bionics worth $36.2M as of Q1 2026.
  • Farallon Capital Management sold 706,000 Beta Bionics shares in Q1 2026, an estimated $10.4M.
  • Beta Bionics made up 0.21% of Farallon Capital Management's portfolio in Q1 2026, its #51 holding.
  • Farallon Capital Management first reported a position in Beta Bionics in Q1 2025 and has held it in 5 quarters since.
  • Farallon Capital Management's Beta Bionics position peaked at $131M in Q4 2025.
  • 130 funds tracked by Wall St. Rank held Beta Bionics as of Q1 2026.

Based on Farallon Capital Management's 13F filing for Q1 2026, filed 15 May 2026.